🟢 Boston Scientific is trading 4.4% up today as shares rebound from FDA-related recall concerns

Boston Scientific is trading 4.4% up at $46.19 as shares rebound following last week’s FDA alert on ENROUTE neuroprotection systems and associated recall concerns.

• Investors appear to be reassessing the long-term fundamentals and the actual impact of the recall risk rather than reacting to new negative headlines.
• The upward movement occurs amid a modestly mixed day for broader U.S. equities, indicating stock-specific strength as the market digests previous volatility.